Benzinga

Benzinga

Benzinga

jueves, agosto 27

Tenax Therapeutics Inc

TENXNASDAQ
Trade with Public
Trade with Public
$2.16
0.041.89%
Últ. Act.: Aug 27, 2:11 PM
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Tenax Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Tenax Therapeutics (TENX).

Price Target Range — 8 Quarters

Analyst Consensus — 9 Analysts

6Buy
3Hold
Consensus RatingBuy# Analysts9Avg. Consensus PT$20Upside to Avg. PT+846.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 11, 2026Chardan CapitalGautam ChukkaDowngradeBuy→Neutral$27→$5
Aug 11, 2026Canaccord GenuityAngela QianPT CutBuy$35→$4
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Chardan Capital Downgrades Tenax Therapeutics to Neutral, Lowers Price Target to $5

Chardan Capital analyst Gautam Chukka downgrades Tenax Therapeutics (NASDAQ:TENX) from Buy to Neutral and lowers the price target from $27 to $5.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Tenax Therapeutics, Lowers Price Target to $4

Guggenheim analyst Seamus Fernandez maintains Tenax Therapeutics (NASDAQ:TENX) with a Buy and lowers the price target from $40 to $4.
Benzinga Newsdesk

PRO
Evercore ISI Group Downgrades Tenax Therapeutics to In-Line, Lowers Price Target to $5

Evercore ISI Group analyst Gavin Clark-Gartner downgrades Tenax Therapeutics (NASDAQ:TENX) from Outperform to In-Line and lowers the price target from $39 to $5.
Benzinga Newsdesk

PRO
William Blair Downgrades Tenax Therapeutics to Market Perform

William Blair analyst Matt Phipps downgrades Tenax Therapeutics (NASDAQ:TENX) from Outperform to Market Perform.
Benzinga Newsdesk

PRO
Canaccord Genuity Initiates Coverage On Tenax Therapeutics with Buy Rating, Announces Price Target of $35

Canaccord Genuity analyst Whitney Ijem initiates coverage on Tenax Therapeutics (NASDAQ:TENX) with a Buy rating and announces Price Target of $35.
Benzinga Newsdesk

PRO
Evercore ISI Group Initiates Coverage On Tenax Therapeutics with Outperform Rating, Announces Price Target of $39

Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Tenax Therapeutics (NASDAQ:TENX) with a Outperform rating and announces Price Target of $39.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved